<?xml version='1.0' encoding='utf-8'?>
<document id="27907909"><sentence text="EGFR kinase inhibitors and gastric acid suppressants in EGFR-mutant NSCLC: a retrospective database analysis of potential drug interaction." /><sentence text="Erlotinib and gefitinib are weak base drugs whose absorption and clinical efficacy may be impaired by concomitant gastric acid suppressive (AS) therapy, yet proton pump inhibitors (PPIs) and histamine-2 receptor antagonists (H2As) are widely indicated in non-small cell lung cancer (NSCLC) patients for the prevention and treatment of erlotinib-induced gastrointestinal injury and corticosteroid-associated gastric irritation"><entity charOffset="0-9" id="DDI-PubMed.27907909.s2.e0" text="Erlotinib" /><entity charOffset="14-23" id="DDI-PubMed.27907909.s2.e1" text="gefitinib" /><entity charOffset="335-344" id="DDI-PubMed.27907909.s2.e2" text="erlotinib" /><entity charOffset="381-395" id="DDI-PubMed.27907909.s2.e3" text="corticosteroid" /><pair ddi="false" e1="DDI-PubMed.27907909.s2.e0" e2="DDI-PubMed.27907909.s2.e0" /><pair ddi="false" e1="DDI-PubMed.27907909.s2.e0" e2="DDI-PubMed.27907909.s2.e1" /><pair ddi="false" e1="DDI-PubMed.27907909.s2.e0" e2="DDI-PubMed.27907909.s2.e2" /><pair ddi="false" e1="DDI-PubMed.27907909.s2.e0" e2="DDI-PubMed.27907909.s2.e3" /><pair ddi="false" e1="DDI-PubMed.27907909.s2.e1" e2="DDI-PubMed.27907909.s2.e1" /><pair ddi="false" e1="DDI-PubMed.27907909.s2.e1" e2="DDI-PubMed.27907909.s2.e2" /><pair ddi="false" e1="DDI-PubMed.27907909.s2.e1" e2="DDI-PubMed.27907909.s2.e3" /><pair ddi="false" e1="DDI-PubMed.27907909.s2.e2" e2="DDI-PubMed.27907909.s2.e2" /><pair ddi="false" e1="DDI-PubMed.27907909.s2.e2" e2="DDI-PubMed.27907909.s2.e3" /></sentence><sentence text=" We assessed the clinical relevance of this potential drug-drug interaction (DDI) in a retrospective cohort of EGFR-mutant NSCLC patients" /><sentence text="" /><sentence text="The AS usage rate was 35%" /><sentence text=" In the overall cohort, AS users did not experience poorer OS (HR: 1" /><sentence text="47, 95% CI: 0" /><sentence text="92 - 2" /><sentence text="35, P = 0" /><sentence text="10; median, 11" /><sentence text="4 versus 17" /><sentence text="5 months) or PFS (HR = 1" /><sentence text="37, 95% CI: 0" /><sentence text="89 - 2" /><sentence text="12, P = 0" /><sentence text="16; median, 7" /><sentence text="6 versus 8" /><sentence text="7 months) compared with non-users in multivariate Cox regression analysis" /><sentence text=" However, subgroup analyses indicated that AS usage was associated with significantly poorer OS and PFS in patients who had fewer or milder comorbidities (Charlson comorbidity index ≤ 2), those with Karnofsky performance status &lt; 90, and never-smokers" /><sentence text="" /><sentence text="A retrospective database analysis of 157 patients given erlotinib or gefitinib for EGFR-mutant advanced NSCLC from two institutions was conducted"><entity charOffset="56-65" id="DDI-PubMed.27907909.s21.e0" text="erlotinib" /><entity charOffset="69-78" id="DDI-PubMed.27907909.s21.e1" text="gefitinib" /><pair ddi="false" e1="DDI-PubMed.27907909.s21.e0" e2="DDI-PubMed.27907909.s21.e0" /><pair ddi="false" e1="DDI-PubMed.27907909.s21.e0" e2="DDI-PubMed.27907909.s21.e1" /></sentence><sentence text=" Patients were classified as AS-users if the periods of AS and anti-EGFR therapy overlapped by ≥ 30%" /><sentence text=" Overall survival (OS) and progression-free survival (PFS) were assessed according to AS usage" /><sentence text="" /><sentence text="Concomitant AS therapy did not have an adverse impact on OS and/or PFS in the overall cohort" /><sentence text=" Our subgroup findings should be regarded exploratory and require replication in a large prospective cohort" /><sentence text="" /></document>